Taxotere Promotional Materials Misleading | DC Metro Area Medical Malpractice Law Blog

Posted by: Salvatore J. Zambri, Esquire

Dow Jones Newswires  reports that the Food and Drug Administration (FDA) has urged Sanofi-Aventis SA, a drug manufacturer, “to stop distributing certain promotional material for its breast cancer drug, Taxotere [docetaxel], saying the material misleadingly claims the medicine is more effective than proven.”  According to the report, the FDA has indicated that “binders with reprinted medical studies claim Sanofi’s Taxotere is better than other medicines to treat patients with breast cancer after prior chemotherapy treatments failed,” yet the “FDA is unaware of substantial evidence to support these claims.”

We encourage our readers to be very careful when reading or listening to promotional materials disseminated by drug companies.  All too often these materials are misleading and are driven by the drug companies’ desire to maximize its profits.   We believe that people should be above profits and that promotional materials must be accurate and properly informative.  If profits are put above people, public health will be compromised.

Our firm has experience pursing cases for patients that involve tragic medication errors, pharmacy mix ups and unsafe medications.  If you think you have been injured by a defective product, we encourage you to read a portion of a book regarding products liability authored by senior partner Salvatore Zambri.

For information about your legal rights, please call Regan Zambri & Long, PLLC at (202) 463-3030 or click here to contact us.